相似文献
1
Fatal pulmonary Mycobacterium xenopi in a patient with rheumatoid arthritis receiving etanercept.
Thorax. 2007 Aug;62(8):739-40. doi: 10.1136/thx.2005.056952.
2
Fatal streptococcal toxic shock syndrome in a patient with rheumatoid arthritis treated with etanercept.
Rheumatology (Oxford). 2005 Sep;44(9):1200-1. doi: 10.1093/rheumatology/keh680. Epub 2005 May 3.
3
Fatal pulmonary Mycobacterium abscessus infection in a patient using etanercept.
Hawaii Med J. 2006 Jan;65(1):12-5.
4
The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.
Int J Rheum Dis. 2009 Jul;12(2):118-24. doi: 10.1111/j.1756-185X.2009.01393.x.
5
6
Mycobacterium mucogenicum: report of a skin infection associated with etanercept.
Dermatol Online J. 2008 Jan 15;14(1):5.
7
Pneumococcal meningitis and etanercept--chance or association?
J Infect. 2005 Aug;51(2):E49-51. doi: 10.1016/j.jinf.2004.08.015.
8
Fatal Mycobacterium peregrinum pneumonia in refractory polymyositis treated with infliximab.
Rheumatology (Oxford). 2005 Sep;44(9):1201-2. doi: 10.1093/rheumatology/keh700. Epub 2005 Jun 7.
9
Management of accelerated pulmonary nodulosis following etanercept therapy in a patient with rheumatoid arthritis.
Rheumatology (Oxford). 2008 Jun;47(6):928-9. doi: 10.1093/rheumatology/ken102. Epub 2008 Apr 2.
10
Disseminated Mycobacterium marinum infection in a patient with rheumatoid arthritis receiving infliximab therapy.
Scand J Infect Dis. 2009;41(4):252-5. doi: 10.1080/00365540902774599.
引用本文的文献
1
Cellular immune responses in HIV-negative immunodeficiency with anti-interferon-γ antibodies and opportunistic intracellular microorganisms.
PLoS One. 2014 Oct 20;9(10):e110276. doi: 10.1371/journal.pone.0110276. eCollection 2014.
2
Paradoxical response to disseminated non-tuberculosis mycobacteriosis treatment in a patient receiving tumor necrosis factor-α inhibitor: a case report.
BMC Infect Dis. 2014 Feb 28;14:114. doi: 10.1186/1471-2334-14-114.
3
Inventory study of non-tuberculous mycobacteria in the European Union.
BMC Infect Dis. 2014 Feb 6;14:62. doi: 10.1186/1471-2334-14-62.
4
Septic shock after seasonal influenza vaccination in an HIV-infected patient during treatment with etanercept for rheumatoid arthritis: a case report.
Clin Vaccine Immunol. 2013 May;20(5):761-4. doi: 10.1128/CVI.00081-13. Epub 2013 Mar 6.
5
Radiological features and therapeutic responses of pulmonary nontuberculous mycobacterial disease in rheumatoid arthritis patients receiving biological agents: a retrospective multicenter study in Japan.
Mod Rheumatol. 2012 Sep;22(5):727-37. doi: 10.1007/s10165-011-0577-6. Epub 2011 Dec 30.
6
Is continuation of anti-tumor necrosis factor-α therapy a safe option for patients who have developed pulmonary mycobacterial infection? : Case presentation and literature review.
Clin Rheumatol. 2012 Feb;31(2):203-10. doi: 10.1007/s10067-011-1902-3. Epub 2011 Dec 15.
7
Nontuberculous mycobacteria and the lung: from suspicion to treatment.
Lung. 2010 Aug;188(4):269-82. doi: 10.1007/s00408-010-9240-9. Epub 2010 Apr 9.
8
Nontuberculous mycobacteria infections and anti-tumor necrosis factor-alpha therapy.
Emerg Infect Dis. 2009 Oct;15(10):1556-61. doi: 10.3201/eid1510.090310.
本文引用的文献
1
Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management.
Lancet Infect Dis. 2003 Mar;3(3):148-55. doi: 10.1016/s1473-3099(03)00545-0.
2
Tumor necrosis factor-alpha antagonists for the treatment of rheumatic diseases.
Curr Opin Rheumatol. 2002 May;14(3):204-11. doi: 10.1097/00002281-200205000-00002.
3
Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent.
N Engl J Med. 2001 Oct 11;345(15):1098-104. doi: 10.1056/NEJMoa011110.
4
Mycobacterium xenopi: innocent bystander or emerging pathogen?
Clin Infect Dis. 1997 Feb;24(2):226-32.
Zotero 插件